NGS In-Depth Focus 2015
9 April 2015 | By Caroline Richards, Editor, Drug Target Review
In this NGS In-Depth Focus; How next-generation sequencing came to be, plus a brief history & Data management for large-scale NGS-based research projects...
List view / Grid view
Articles
Drug Targets In-Depth Focus 2015
9 April 2015 | By J.R.Costa, J.Heintze, R.Ketteler, S. Gul, Dr. T.Duensing, K.Papenfuss.
In this Drug Targets In-Depth Focus, we delve into the role of a key complex required for autophagosome maturation, the ATG4-ATG8 conjugation system, and we provide insight on some up-and-coming immune checkpoint inhibitors that are currently in clinical and preclinical development...
Academic high-throughput screening; Opportunities for change
Tim Hammonds from Cancer Research Technology Discoveries explains how academic HTS laboratories came into being and outlines the challenges facing the new HTS model...
The impact of phenotypic and functional screening in CNS drug discovery
Wolfgang Fecke and Christine Williams from UCB discuss the industry’s approach to drug discovery with costs escalating and output failing to achieve the corresponding increases in revenue...
Label-free technologies for monitoring drug interactions
In his fascinating overview of label-free analysis, Dr. Masson introduces the four main label-free methods: physical, electrochemical, mass-based and optical techniques, before providing the reader with in-depth insight into the most common label-free technique within the pharmaceutical industry: surface plasmon resonance (SPR)...
Evaluation of a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening
This article evaluates a GADD45a-GFP human cell assay for rapid and reliable in vitro early genotoxicity screening...
The quest for accurate target validation
Preview of the upcoming foreword in our April issue, written by Sheraz Gul, Vice President and Head of Biology at Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Hamburg, Germany...
The promise of induced pluripotent stem cells for liver disease, toxicology and drug discovery
We discuss the steps required for differentiating human pluripotent stem cells into hepatocyte-like cells, and how long this process takes and the quality control measures needed...
Workshop Review: Cell-based Assays for Screening (December 2014)
Sheraz Gul, Head of Biology at Fraunhofer-IME SP, provides an in-depth review of the Cell-Based Assays for Screening workshop which took place in December 2014...
Meet the editorial board members who influenced the Spring 2015 issue
Editor Caroline Richards talks about the editorial board members who have influenced the content coming up in the latest issue of Drug Target Review, available in April 2015...
How next-generation sequencing came to be: a brief history
DNA sequencing technologies have come on leaps and bounds since the double-helical structure of DNA was first discovered in 1953 by genetics pioneers James Watson and Francis Crick. This discovery paved the way to the development, years later, of next generation sequencing (NGS), a high-throughput technology that enables scientists to…
Formation of nano- and micro-scale drug delivery systems using microfluidic technology
The recent developments in microfluidic technology have provided an effective microreactor platform for the production of a range of pharmaceutically related materials in both nano- and micro-scale. This can be attributed to the unique characteristics that microfluidic-based reactors offer in terms of controllability and uniformity of the material characteristics, compared…
Neutrons: homing in on more targeted drug delivery
Neutrons, electrically neutral particles found within the nucleus of the atom, are coming into their own in the exploration of new ways to get drugs to their targets. Neutron techniques are being used to investigate innovative new approaches to drug delivery that could increase the effectiveness of treatments, improve the…
Synthetic macrocyclic receptors as tools in drug delivery and drug discovery
Macrocyclic compounds (see Figure 1) have fascinated medicinal chemists for generations. The first ones which have been characterised are the naturally occurring cyclodextrins (CDs), cyclic oligomers of glucose, which can be obtained by bacterial synthesis from starch. Calixarenes (CXs) were among the first man-made macrocycles, followed by crown ethers (Pedersen,…
Antibody Discovery Technologies: the partnership between academia and biopharma in the therapeutic monoclonal antibody success story
The use of monoclonal antibodies and antibody-based molecules as therapeutics to treat patients suffering with severe disease has become a major success story. Due to the exquisite specificity with which they interact with their antigen and the fact that their large binding surface can intervene at sites and targets not…
